← Back to Screener
Ernexa Therapeutics Inc. Warrants (ERNAW)
Price$0.12
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (4W)59.74%
VGM Score86.20
All Metrics
Price vs S&P 500 (YTD)10.11%
10-Day Avg Trading Volume0.04M
3-Month Avg Trading Volume0.05M
52-Week High$0.23
Year-to-Date Return19.80%
5-Day Price Return2.83%
Month-to-Date Return-4.24%
52-Week Low$0.02
mGradeA
vgmGradeA
Show chart for
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ERNAWErnexa Therapeutics Inc. Warrants | — | — | A | $0.12 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Ernexa Therapeutics develops cell-based medicines for cancer and autoimmune diseases using proprietary technology that transforms iPSCs into iMSCs. The platform generates off-the-shelf treatment solutions without patient-specific cell harvesting, potentially offering advantages in scalability and manufacturing efficiency.